MAF Test Expands Global Reach

Inbiomotion and its partners have signed exclusivity deals that move the single-gene MAF Test® beyond Iberia into key international markets. Source BioScience will offer the assay as a service across the United Kingdom and Ireland, giving an estimated 56,000 early-stage breast-cancer patients each year access to a prognostic tool that guides adjuvant bisphosphonate use. SPA Farma has secured distribution rights for Italy, where the test could benefit around 55,000 new patients annually.

These agreements position the IRB Barcelona spin-off to establish its precision, FISH-based assay as a global standard for identifying women at high risk of bone metastasis—while sparing low-risk patients unnecessary treatment.

More information: Inbiomotion and Source BioScience sign an exclusive agreement for MAF Test® in United Kingdom and Ireland, Inbiomotion and SPA - Società Prodotti Antibiotici (SPA Farma) sign an exclusive agreement for MAF Test® in Italy,